Rize Oncology
Turning the Tide on Metastasis
At Rize Oncology, we are developing STS-201 for the treatment of soft tissue sarcoma.
STS-201
STS-201 is a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, as well as other types of cancers and certain proliferative diseases. The unique mechanism of action of STS-201 results in:
- A blockade of cell division at the late G2/M boundary, a site in the cell cycle that is believed to be optimal for radiation-induced damage.
- A slowing of the rate of tumor proliferation, which enables normalization of the tumor neo-vasculature. The result is better oxygenation and more efficient drug delivery.
- Increased oxygen in the tumor micro-environment, which increases sensitivity to radiation due to radiation-induced formation of reactive oxygen species.
- Formation of a more complete tumor vasculature, which reduces the poorly formed, disorganized vascular sites where metastatic cells penetrate the circulatory system.
Soft Tissue Sarcoma
Soft tissue sarcomas are a rare, diverse and often rapidly fatal group of tumors consisting of more than 100 different subtypes that are estimated to account for about 1% of all cancers in adults and 7% in children. Treatment of STS is an immediate unmet medical need. STS tumors can occur anywhere within the body, including muscle, fat, nerves, vascular tissue, and other connective tissues. Median survival after development of distant metastases is estimated to be 11 to 18 months, but this varies significantly based on primary histologic subtype and treatment paradigms.
Based on the prevalence of STS in the United States, we believe it is a rare disease and that STS-201 for the treatment of STS may qualify for Orphan Drug status.